PIPELINE
OB002
OB002 is a preclinical monoclonal antibody program aimed at a biomarker-linked inflammatory axis in obesity-associated cardiovascular disease. We translate a disease-relevant signal into a targeted antibody approach—with epitope logic, functional endpoints, and a clinical path built in from day one.
OB002 targets a mechanistically implicated inflammatory mediator (LCN2) that tracks with obesity and cardiometabolic dysfunction. Our strategy is designed to modulate downstream remodeling and fibrosis signals—prioritizing functional impact and translation, not just binding.
OB002 is developed through an antibody workflow that couples epitope-aware design with mechanistic screening and disease-relevant functional readouts. Lead selection emphasizes biophysical quality and scale-up readiness to support IND execution.
We share full figures and protocols with qualified partners.